Does the MTHFR A1298C AC genotype have a smaller functional effect than higher-impact MTHFR genotypes?

MTHFR is a central folate-cycle enzyme, and the claim is supported overall. Its clinical meaning, however, depends more on measured metabolic status and nutrient context than on an isolated common-variant result.

Mechanistic evidence

• MTHFR catalyzes the physiologically irreversible conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate (5-MTHF), using FAD as a redox cofactor and preferentially NADPH as electron donor.
• 5-MTHF supplies the methyl group for vitamin-B12-dependent methionine synthase, which converts homocysteine to methionine and regenerates tetrahydrofolate for re-entry into the folate cycle.
• MTHFR therefore supports homocysteine remethylation upstream; it does not itself methylate homocysteine. The separate betaine-dependent BHMT pathway can also remethylate homocysteine.

Genotype-related functional implications

• A1298C heterozygosity (AC) can modestly reduce MTHFR enzyme function, but AC alone has not consistently produced lower circulating 5-MTHF or higher homocysteine.
• This is generally less consequential than MTHFR C677T homozygosity (TT), which is more consistently linked to reduced enzyme activity and higher homocysteine, particularly with low folate status. Reported activity reductions for C677T TT are approximately 50–70% relative to reference CC.
• Compound C677T/A1298C heterozygosity may retain roughly 50–60% activity and should not be equated with A1298C AC alone.

Clinical interpretation

• Severe inherited MTHFR deficiency illustrates the pathway’s importance: low 5-MTHF occurs with elevated homocysteine and low methionine. Common A1298C AC carriage is not comparable to this disorder.
• Folate and vitamin B12 status, among other determinants, materially influence homocysteine; direct homocysteine measurement and nutritional assessment are more clinically informative than AC status alone when evaluation is indicated.

Bottom line

• A1298C AC generally has a smaller functional and metabolic effect than higher-impact MTHFR genotypes, especially C677T TT; by itself, it does not establish clinically important impairment or predict an individual homocysteine level.